仟源医药: 关于回购注销2024年限制性股票激励计划部分限制性股票的公告

Core Points - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. announced the repurchase and cancellation of 60,000 restricted stocks from the 2024 incentive plan due to one incentive object leaving the company [1][4][8] - The repurchase price is set at 4.73 yuan per share, with interest equivalent to the bank's term deposit rate [1][6] - The total amount for the repurchase is 283,800 yuan, sourced from the company's own funds [6][8] Decision Process and Disclosure - The decision to repurchase was approved during the 31st meeting of the fifth board of directors on August 8, 2025, following the necessary procedures and disclosures [1][4] - The supervisory board confirmed that no objections were raised during the public notice period regarding the incentive plan [2][4] Stock Structure Changes - Before the repurchase, the total number of restricted shares was 21,014,468, which will decrease to 20,954,468 after the cancellation [7] - The total share capital will change from 248,318,563 to 248,258,563 shares [7] Impact on the Company - The repurchase and cancellation of the restricted stocks will not significantly affect the company's financial status, operational results, or the ongoing implementation of the incentive plan [4][8] - The management team is committed to fulfilling their responsibilities and creating value for shareholders [4][8] Committee and Legal Opinions - The Compensation and Assessment Committee approved the repurchase, confirming compliance with relevant regulations and the accuracy of the number and price of the stocks [8] - Legal opinions from Guohao Law Firm indicate that the company has obtained necessary approvals and must submit the matter for shareholder approval [8]